KLK3 and prostate cancer: Although conventional biomarkers are still used in clinics, such as serum chromogranin, 5-HIAA and neuron-specific enolase for NET, and serum PSA for prostate cancer, these fall short when tumors with mixed cellular patterns are presented to outpatient departments.